Lifeboat Foundation

Improving Quality Of Life & Health, For Hundreds Of Millions Globally, Suffering Food Allergies & Intolerances — Lisa Gable, Chief Executive Officer, Food Allergy Research & Education (FARE)

Lisa Gable is the Chief Executive Officer, of Food Allergy Research & Education (FARE — https://www.foodallergy.org), an organization with a mission to improve the quality of life and the health of 85 million Americans with food allergies and food intolerances, including 32 million of those are at risk for life-threatening anaphylaxis, and to provide them hope through the promise of new treatments. To date FARE has turned over $100 million in donor gifts into ground-breaking research and has provided a voice for the community, advocating on its behalf and offering hope for a better tomorrow.

Continue reading “Lisa Gable — Chief Executive Officer — Food Allergy Research & Education (FARE)” »

A ‘deadly fungal infection’ that can be resistant to all existing treatments has been worrying health officials following recent outbreaks in hospitals and care homes around the USA

Dailystar.

Tetra’s trial will be the first worldwide drug which involves the use of an injectable sterile synthetic cannabinoid in patients infected by COVID-19. Tetra will use this study to demonstrate that its ARDS-003 drug can help prevent the acute respiratory distress seen in serious complications of COVID-19.

The proposed study is a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ascending doses of ARDS-003 in hospitalized COVID-19 patients with pneumonia and at risk of developing acute respiratory distress syndrome.

Seeking guidance on clinical study protocol to be conducted in patients with COVID-19 is a pre-requisite of the Health Canada regulatory process for COVID-related trials. The Office of Clinical Trials of Health Canada’s Therapeutic Products Directorate acknowledged that Tetra’s extensive nonclinical data, including genotoxicity, safety pharmacology and toxicities studies, assessing the safety and pharmacokinetic profile of the investigational drug meet the authority’s requirements for a New Molecular Entity and granted the Company the approval for filing a clinical trial application in patients infected with Sars-CoV-2 (COVID-19). The authorities also agreed on the proposed study design, target population, and primary and secondary objectives and endpoints of the study in severe COVID-19 patients. To this end, contingent to Health Canada’s accelerated review process for Covid-related trials, the Company’s drug ARDS-003, will be evaluated in COVID-19 patients.

💠 Japanese researchers have created a “nose” mosquito that can detect odors from tiny droplets of liquid droplets. The research could lead to the creation of Smell-O-Vision for machines and a means of diagnosing early cancer, they say. Japanese researchers have created a “nose” that can detect different odors at the same time. The team used two bubbles, each filled with oil, broken horizontally, to create a squinted figure-eight. They hope to use it to develop an artificial nose in the future.

Researchers have developed a “bionic nose” that can detect odor molecules. The team hopes to use the device as an inexpensive way to diagnose the early stages of illness. Eventually, the team wants to use their bionic nose for cancer and other health issues. They hope to make the device available to the public soon.

Continue reading “Scientists Made a Biohybrid Nose Using Cells From Mosquitoes” »

After the New Shepard rocket vehicle carried Jeff Bezos, his brother Mark, Wally Funk and Oliver Daemen into space and its capsule glided safely back to the West Texas desert, the four crewmates emerge safely and are greeted by their jubilant families.

» Subscribe to TODAY: http://on.today.com/SubscribeToTODAY
» Watch the latest from TODAY: http://bit.ly/LatestTODAY

Continue reading “See Jeff Bezos Emerge Safely From Capsule After Blue Origin Space Launch” »

On the first passenger test flight for his space company Blue Origin, Jeff Bezos blasted into space from West Texas along with his brother Mark Bezos, 82-year-old aviator Wally Funk and 18-year-old physics student Oliver Daemen aboard the rocket New Shepard. NBC’s Tom Costello reports for TODAY from Corn Ranch, Texas.

» Subscribe to TODAY: http://on.today.com/SubscribeToTODAY
» Watch the latest from TODAY: http://bit.ly/LatestTODAY

Continue reading “See Jeff Bezos Launch Into Space With Blue Origin Crew” »

CHAPEL HILL, N.C. – Scientists at the University of North Carolina Gillings School of Global Public Health have developed a vaccine that could be effective against COVID-19, its variants — and a future coronavirus pandemic.

While no one knows which virus may cause the next outbreak, coronaviruses remain a threat after causing the SARS outbreak in 2003 and the global COVID-19 pandemic.

According to a study published June 22 in Science, the vaccine designed at UNC-Chapel Hill protected mice from the current SARS-CoV-2 coronavirus, plus a group of coronaviruses known to make the jump from animals to humans.

All cancers fall into just two categories, according to new research from scientists at Sinai Health, in findings that could provide a new strategy for treating the most aggressive and untreatable forms of the disease.

In new research out this month in Cancer Cell, scientists at the Lunenfeld-Tanenbaum Research Institute (LTRI), part of Sinai Health, divide all cancers into two groups, based on the presence or absence of a protein called the Yes-associated protein, or YAP.

Rod Bremner, senior scientist at the LTRI, said they have determined that all cancers are present with YAP either on or off, and each classification exhibits different drug sensitivities or resistance. YAP plays an important role in the formation of malignant tumours because it is an important regulator and effector of the Hippo signaling pathway.